Linda Stein Gold

18PUBLICATIONS
74CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological methodsDisease surveillancePrecision engineeringAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Aug 28, 2026
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials.

|May 21, 2026
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

|Oct 13, 2025
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.

Matthias Augustin, Marie Tauber, Robert Sidbury

|Jul 18, 2025
The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA).

Jennifer Soung, Vivian Laquer, Matthew Zirwas

|Jul 02, 2025
Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis.

Linda Stein Gold, Matthew J Bruno, G Michael Lewitt

|Jan 12, 2025
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.

Linda Stein Gold, James Del Rosso, Benjamin D Ehst

Pageof 3

Frequent Collaborators

4 joint publications

Matthias Augustin

4 joint publications

Kim Papp

4 joint publications

James Q Del Rosso

3 joint publications

Andreas Pinter